The PD-1/PD-L1 Pathway in Human Pathology

被引:87
|
作者
Saresella, M. [1 ]
Rainone, V. [2 ]
Al-Daghri, N. M. [3 ]
Clerici, M. [1 ,2 ,4 ]
Trabattoni, D. [4 ]
机构
[1] ONLUS, Don C Gnocchi Fdn, I-20148 Milan, Italy
[2] Univ Milan, Dept Biomed Sci & Technol, I-20133 Milan, Italy
[3] King Saud Univ, Biomarker Res Program, Dept Biochem, Coll Sci, Riyadh 11451, Saudi Arabia
[4] Univ Milan, Chair Immunol, Milan, Italy
关键词
Alzheimer's disease; autoimmunity; costimulation; HIV infection; immune tolerance; multiple sclerosis; PD-1; PD-L1; T-cell activation; REGULATORY T-CELLS; B7; FAMILY; MULTIPLE-SCLEROSIS; NEGATIVE REGULATION; INDUCED EXPRESSION; 2ND LIGAND; B7-H1; RECEPTOR; SUPERFAMILY; CTLA-4;
D O I
10.2174/156652412799218903
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
T-cell activation is dependent on signals delivered through the antigen-specific T-cell receptor and accessory receptors on T-cells. Integration of signals through this family of costimulatory and inhibitory receptors and their ligands regulates the balance between T-cell activation, tolerance, and immunopathology. Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals and exert a vital and diverse range of immunoregulatory roles in T-cell activation, tolerance, and immune-mediated tissue damage. In this review, we revisit current understanding of the immunoregulatory functions of PD-1 and its ligands and their involvement in immune-mediated diseases.
引用
收藏
页码:259 / 267
页数:9
相关论文
共 50 条
  • [1] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [2] A snapshot of the PD-1/PD-L1 pathway
    Ghosh, Chinmoy
    Luong, Gary
    Sun, Yue
    JOURNAL OF CANCER, 2021, 12 (09): : 2735 - 2746
  • [3] Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
    Ohaegbulam, Kim C.
    Assal, Amer
    Lazar-Molnar, Eszter
    Yao, Yu
    Zang, Xingxing
    TRENDS IN MOLECULAR MEDICINE, 2015, 21 (01) : 24 - 33
  • [4] PD-1/PD-L1 Pathway in Breast Cancer
    Schuetz, Florian
    Stefanovic, Stefan
    Mayer, Luisa
    von Au, Alexandra
    Domschke, Christoph
    Sohn, Christof
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (05) : 294 - 297
  • [5] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
    Saito, Hiroaki
    Kono, Yusuke
    Murakami, Yuki
    Shishido, Yuji
    Kuroda, Hirohiko
    Matsunaga, Tomoyuki
    Fukumoto, Yoji
    Osaki, Tomohiro
    Ashida, Keigo
    Fujiwara, Yoshiyuki
    ANTICANCER RESEARCH, 2018, 38 (01) : 107 - 112
  • [6] The regulation of PD-1/PD-L1 pathway and autoimmune diseases
    Okazaki, T
    Iwai, Y
    Nishimura, H
    Honjo, T
    ACTIVATING AND INHIBITORY IMMUNOGLOBULIN-LIKE RECEPTORS, 2001, : 211 - 214
  • [7] The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis
    Ahn, Julie
    Bishop, Justin A.
    Roden, Richard B. S.
    Allen, Clint T.
    Best, Simon R. A.
    LARYNGOSCOPE, 2018, 128 (01): : E27 - E32
  • [8] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
    Barclay, Jonathan
    Creswell, Joanne
    Leon, Juan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
  • [9] PD-1/PD-L1 pathway: current researches in cancer
    Han, Yanyan
    Liu, Dandan
    Li, Lianhong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (03): : 727 - 742
  • [10] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
    Guo, Jiazheng
    Yu, Fengyi
    Zhang, Kuojun
    Jiang, Sheng
    Zhang, Xiangyu
    Wang, Tianyu
    RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108